C3435T polymorphism of MDR1 gene with warfarin resistance

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 34-36

  Kim, Yeongsic ^a   Smith, Andrew ^b   Wu, Alan H B ^b  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C3435T polymorphism; MDR1 gene; Warfarin resistance

Indexed keywords

WARFARIN;

ADULT; AFRICAN AMERICAN; ANTICOAGULATION; ARTICLE; ASIAN AMERICAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; DRUG RESISTANCE; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPEAN AMERICAN; FEMALE; GENE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HISPANIC AMERICAN; HUMAN; HUMAN CELL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; PRIORITY JOURNAL; TREATMENT DURATION; WARFARIN RESISTANCE;

C3435T POLYMORPHISM; MDR1 GENE; WARFARIN RESISTANCE;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CONTINENTAL POPULATION GROUPS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY EMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 84881224598     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.010     Document Type: Article

References (22)

1. Dentali F., Donadini M.P., Clark N., et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy 2011, 31:386-393.
2. Gage B.F., Eby C., Johnson J.A., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
3. Muszkat M., Blotnik S., Elami A., et al. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther 2007, 29:427-437.
4. Wu A.H., Wang P., Smith A., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008, 9:169-178.
5. Wu A.H., Shin J. MDR1 polymorphism and warfarin resistance detection: is this the missing link?. Pers Med 2011, 8:611-612.
6. De Oliveira Almeida V.C., De Souza Ferreira A.C., Ribeiro D.D., et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemost 2011, 9:2120-2122.
7. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011, 201:261-283.
8. Wandel C., Kim R.B., Kajiji S., et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999, 59:3944-3948.
9. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction?. Drug Metab Pharmacokinet 2005, 20:391-414.
10. Wadelius M., Sörlin K., Wallerman O., et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004, 4:40-48.
11. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
12. Leschziner G.D., Andrew T., Pirmohamed M., et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007, 7:154-179.
13. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003, 55:53-81.
14. Lazarowski A.J., García Rivello H.J., Vera Janavel G.L., et al. Cardiomyocytes of chronically ischemic pig hearts express the MDR-1 gene-encoded P-glycoprotein. J Histochem Cytochem 2005, 53:845-850.
15. Müller F., Fromm M.F. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011, 12:1017-1037.
16. Schuetz E.G., Furuya K.N., Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995, 275:1011-1018.
17. Perloff M.D., von Moltke L.L., Störmer E., et al. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001, 134:1601-1608.
18. Dürr D., Stieger B., Kullak-Ublick G.A., et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000, 68:598-604.
19. Ghanem C.I., Arias A., Novak A., et al. Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol 2011, 81:244-250.
20. Burk O., Brenner S.S., Hofmann U., et al. The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin Pharmacol Ther 2010, 88:685-694.
21. Riganti C., Campia I., Polimeni M., et al. Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. Toxicol Appl Pharmacol 2009, 240:385-392.
22. Ghanem C.I., Gómez P.C., Arana M.C., et al. Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol 2004, 68:791-798.